Trials / Completed
CompletedNCT05836506
A Study to Assess the Relative Bioavailability of Immediate Release Formulations of ABBV-903 in Healthy Adult Participants
Assessment of the Relative Bioavailability of Immediate Release Formulations of ABBV-903 in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The main objective of this study is to assess the relative bioavailability and pharmacokinetics of ABBV-903 in healthy adult participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABBV-903 Tablet Form 1 | Oral Tablets |
| DRUG | ABBV-903 Tablet Form 2 | Oral Tablets |
Timeline
- Start date
- 2023-04-18
- Primary completion
- 2023-06-20
- Completion
- 2023-06-20
- First posted
- 2023-05-01
- Last updated
- 2023-07-17
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05836506. Inclusion in this directory is not an endorsement.